Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $9.60 and traded as high as $9.93. Astellas Pharma shares last traded at $9.65, with a volume of 268,454 shares.
Astellas Pharma Stock Performance
The firm's fifty day moving average price is $9.61 and its 200 day moving average price is $10.03. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $18.21 billion, a price-to-earnings ratio of -45.74 and a beta of 0.31.
Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last issued its quarterly earnings data on Friday, April 25th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.15 by $0.12. Astellas Pharma had a negative net margin of 3.10% and a positive return on equity of 13.69%. The firm had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.02 billion. Analysts forecast that Astellas Pharma Inc. will post 0.42 EPS for the current fiscal year.
Astellas Pharma Company Profile
(
Get Free Report)
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.
Featured Stories
Before you consider Astellas Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astellas Pharma wasn't on the list.
While Astellas Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
